A proof of biological efficacy study assessing the potential of piboserod, a specific 5-HT4 antagonist, for the treatment of symptomatic congestive heart failure in stable outpatients (NYHA class II-IV) on top of usual evidence based pharmacological..

Trial Profile

A proof of biological efficacy study assessing the potential of piboserod, a specific 5-HT4 antagonist, for the treatment of symptomatic congestive heart failure in stable outpatients (NYHA class II-IV) on top of usual evidence based pharmacological..

Not stated
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 01 Dec 2006

At a glance

  • Drugs Piboserod (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top